X

Trial Profile

SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Nov 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Paclitaxel
Indications Coronary artery disease; Coronary artery restenosis
Focus Registrational; Therapeutic Use
Acronyms SPIRIT-III
Sponsors Abbott Laboratories

Most Recent Events

11 Nov 2011 Four-year results presented at the 23rd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
04 Nov 2011 Five-year results will be presented at the 23rd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics (TCT-2011), according to an Abbott media release.
05 Apr 2011 Pooled analysis results presented at the 60th Annual Scientific Session of the American College of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com